We are live on ! Find out more
GILD icon

Gilead Sciences

1,263 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 83

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1891,263 (+74)

0% less capital invested

Capital invested by funds: $116B → $116B (-$569M)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,263
Holders Change
+74
Holders Change %
+6.22%
% of All Funds
36.28%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.71%
New
163
Increased
527
Reduced
461
Closed
83
Calls
$2B
Puts
$2.62B
Net Calls
-$624M
Net Calls Change
+$552M
Name Holding Trade Value Shares
Change
Change in
Stake
AI
176
Axiom Investors
Connecticut
$69.8M -$4.78M -61,450 -7%
State of Tennessee, Department of Treasury
177
State of Tennessee, Department of Treasury
Tennessee
$69.8M -$36M -462,213 -35%
Caisse de Depot et Placement du Quebec (CDPQ)
178
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$69.6M -$3.34M -42,900 -5%
CEP
179
Chicago Equity Partners
Illinois
$69.3M +$23.8M +305,205 +57%
KCM
180
Kames Capital Management
United Kingdom
$67.5M +$19.7M +252,846 +45%
STC
181
SEI Trust Company
Pennsylvania
$67M -$55.4M -711,103 -47%
TG
182
TCW Group
California
$63.8M +$393K +5,050 +0.7%
RIM
183
Rainier Investment Management
Washington
$63.5M -$59.5M -764,034 -50%
MSA
184
Mason Street Advisors
Wisconsin
$63.1M -$8.53M -109,556 -13%
DekaBank Deutsche Girozentrale
185
DekaBank Deutsche Girozentrale
Germany
$62.8M -$3.76M -48,295 -6%
BTS
186
BB&T Securities
Virginia
$61.9M +$346K +4,445 +6%
NAM
187
NorthCoast Asset Management
Connecticut
$61.5M +$1.66M +21,369 +3%
Aviva
188
Aviva
United Kingdom
$61.3M +$31.1K +400 +0.1%
Royal London Asset Management
189
Royal London Asset Management
United Kingdom
$60.9M +$18M +230,912 +54%
AIG
190
American International Group
New York
$60.8M +$2.64M +33,966 +5%
EA
191
Euclid Advisors
Connecticut
$60.5M -$22.5M -288,652 -28%
CII
192
Capital International Inc
California
$59.4M -$18.4M -236,600 -25%
TAM
193
Tiverton Asset Management
Delaware
$58M +$31.1M +400,000 +133%
N
194
Nuveen
North Carolina
$57.5M -$11.5M -147,692 -18%
VRS
195
Virginia Retirement Systems
Virginia
$57.3M +$10M +129,065 +23%
MVP
196
Miller Value Partners
Florida
$55.6M +$52.2M +670,075 New
AAP
197
Ardsley Advisory Partners
Connecticut
$55.5M +$41.9M +538,000 +408%
GA
198
Geneva Advisors
Illinois
$54.9M -$32.5M -417,964 -39%
MCM
199
McKinley Capital Management
Alaska
$54.6M -$2.51M -32,236 -5%
Comerica Bank
200
Comerica Bank
Texas
$54M -$10.1M -129,129 -17%

GILD Hedge Fund Activity: Q2 2014 in Review

1,263 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $116B — down 0.49% from $116B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new GILD positions and 83 closed out — a net gain of 80 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,263 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,189 in Q1 2014.
  • Funds reported $116B of Gilead Sciences stock for Q2 2014, down 0.49% quarter-over-quarter.
  • 163 funds opened new Gilead Sciences positions in Q2 2014 and 83 closed out, a net change of +80 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.